Search

Your search keyword '"W. Sulowicz"' showing total 82 results

Search Constraints

Start Over You searched for: Author "W. Sulowicz" Remove constraint Author: "W. Sulowicz"
82 results on '"W. Sulowicz"'

Search Results

2. DIALYSIS CARDIOVASCULAR COMPLICATIONS 1

3. CLINICAL ACUTE KIDNEY INJURY 2

4. Peritoneal dialysis - A

5. Transplantation: clinical studies - A

6. Peritoneal dialysis

7. Mineral and bone disease - CKD 5D

8. Cardiovascular complications in CKD 5D

9. Pathogenesis and treatment of dialysis hypotension

10. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study

11. The effects of cinacalcet in older and younger patients on hemodialysis: The evaluation of cinacalcet HCL therapy to lower cardiovascular events (EVOLVE) trial

12. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study

13. Single-dose pharmacokinetics of felbamate in patients with renal dysfunction

15. PO17-495 VALUE OF DOPPLER ULTRASONOGRAPHY IN RENAL ARTERY STENOSIS RECOGNITION

16. Diabetes - Clinical studies

17. Protein-energy wasting, inflammation and oxidative stress in CKD 5D

19. Diabetes mellitus - clinical studies - 2

20. Beta-glucuronidase activity in neutrophils of patients with malignancies

22. Second Nephrology Summer School

24. The effect of renal function on felbamate clearance

25. Immunological parameters in patients with gastric cancer at different clinical stages

26. Activity of some lysosomal enzymes in neutrophils from peripheral blood of patients with digestive tract cancer at different clinical stages of the disease. A cytochemical study

28. The neutrophil and lymphocyte nonspecific esterase in patients with malignancies

30. Cytochemical study on the glycogen content in neutrophils from peripheral blood of patients with gastrointestinal cancer

33. Random migration of leukocytes and phagocytic activity of neutrophils in patients with cancer of gastrointestinal tract at different clinical stages

35. Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment.

36. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).

37. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.

38. Clinicopathologic correlations of renal pathology in the adult population of Poland.

39. The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients.

40. Imaging of inflamed carotid artery atherosclerotic plaques with the use of 99mTc-HYNIC-IL-2 scintigraphy in end-stage renal disease patients.

41. Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function.

42. C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease.

43. [Kaposi's sarkoma in solid organ recipients].

44. Identification of inflamed atherosclerotic plaque using 123 I-labeled interleukin-2 scintigraphy in high-risk peritoneal dialysis patients: a pilot study.

45. Two consecutive cases of renal oncocytomatosis in a single-center experience.

46. Prevalence and prediction of renal artery stenosis in patients with coronary and supraaortic artery atherosclerotic disease.

47. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.

48. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

49. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk.

50. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.

Catalog

Books, media, physical & digital resources